Kiora Pharmaceuticals Secures New U.S. Patent for Novel KIO-100 Formulations

Kiora Pharmaceuticals 获得新型 KIO-100 制剂的美国新专利

December 02, 2025

2025年12月02日

Kiora Pharmaceuticals has received a new U.S. patent (Patent No. 12,472,263) covering additional and novel formulations of the KIO-100 family of compounds, further strengthening the intellectual property portfolio for its pipeline of non-steroidal anti-inflammatory therapies. This announcement follows the July 2025 issuance of a previous patent (Patent No.

Kiora Pharmaceuticals获得了另一项美国专利（专利号12,472,263），涵盖KIO-100化合物家族的其他新型制剂，进一步增强了其非甾体抗炎治疗产品线的知识产权组合。此次公告紧随2025年7月颁发的前一项专利（专利号）。

12,364,680) related to KIO-104, the company’s lead ocular therapy..

12,364,680）与公司的主要眼部治疗药物KIO-104相关。

Novel Formulation Targets Retinal Inflammation

新型制剂靶向视网膜炎症

The newly granted patent protects a novel formulation of the active pharmaceutical ingredient (API) in KIO-104, a non-steroidal small molecule inhibitor of dihydroorotate dehydrogenase (DHODH). Unlike steroids or systemic anti-inflammatories, KIO-104 offers a targeted approach by inhibiting DHODH, a mitochondrial enzyme essential in the synthesis of DNA and RNA.

新授予的专利保护了 KIO-104 中活性药物成分 (API) 的一种新型配方，KIO-104 是一种非甾体类小分子二氢乳清酸脱氢酶 (DHODH) 抑制剂。与类固醇或全身性抗炎药不同，KIO-104 通过抑制 DHODH 这种在线粒体中对 DNA 和 RNA 合成至关重要的酶，提供了针对性的方法。

This mechanism positions KIO-104 as a promising alternative in the treatment of retinal inflammatory diseases..

该机制使KIO-104成为治疗视网膜炎症疾病的一个有前景的替代方案。

According to Brian M. Strem, PhD, President & CEO of Kiora Pharmaceuticals, “We believe DHODH inhibitors have significant potential to slow, stop, or reverse inflammatory-related vision loss, where steroids or biologics are not providing appropriate benefit today.”

根据Kiora Pharmaceuticals公司总裁兼首席执行官Brian M. Strem博士的说法：“我们相信DHODH抑制剂在减缓、阻止或逆转与炎症相关的视力丧失方面具有显著潜力，而目前类固醇或生物制剂未能提供适当的疗效。”

Advancing Clinical Development: KIO-104 in Phase 2 KLARITY Trial

推进临床开发：KIO-104 在二期 KLARITY 试验中

KIO-104 has already demonstrated clinical proof-of-concept in a Phase 1 trial for non-infectious uveitis. The company is now enrolling patients in Phase 2 of the KLARITY trial, a multicenter study evaluating higher doses of KIO-104 in posterior non-infectious uveitis and diabetic macular edema, as well as other forms of retinal inflammation..

KIO-104已经在一项针对非感染性葡萄膜炎的1期临床试验中展示了临床概念验证。该公司现在正在招募患者参与KLARITY试验的2期阶段，这是一项多中心研究，评估KIO-104更高剂量在后部非感染性葡萄膜炎、糖尿病性黄斑水肿以及其他形式的视网膜炎症中的效果。

The ongoing KLARITY study will involve up to 28 patients across two dosing levels, with results from the initial stage guiding future dose expansion strategies.

正在进行的KLARITY研究将涉及两个剂量水平的最多28名患者，初始阶段的结果将指导未来的剂量扩展策略。